Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Status:
Terminated
Trial end date:
2017-01-13
Target enrollment:
Participant gender:
Summary
This is an open label, multi-institutional, single arm phase II trial of pembrolizumab in
patients with incurable platinum refractory germ cell tumors. No randomization or blinding is
involved.
Phase:
Phase 2
Details
Lead Sponsor:
Nasser Hanna, M.D.
Collaborators:
Hoosier Cancer Research Network Merck Sharp & Dohme Corp.